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What is the key question? 34 
Is Physiotherapy, speech and language therapy intervention (PSALTI) effective for patients 35 
with refractory chronic cough? 36 
 37 
What is the bottom line? 38 
PSALTI significantly reduced objective cough frequency and significantly improved quality 39 
of life when compared to control intervention. 40 
 41 
Why read on? 42 
This study is the first multi-centred randomised controlled trial that demonstrates 43 
improvements with Physiotherapy and Speech and Language Therapy Intervention (PSALTI) 44 
compared to control intervention using objective outcome measures.  45 
 46 
Twitter Feed (140 characters including spaces): Physiotherapy, speech and language therapy 47 
(PSALTI) reduces cough and improves quality of life in refractory chronic cough patients 48 
 49 
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ABSTRACT  75 
Background Physiotherapy and Speech and Language Therapy are emerging non-76 
pharmacological treatments for refractory chronic cough. We aimed to investigate the 77 
efficacy of a Physiotherapy, Speech and Language Therapy Intervention (PSALTI) to 78 
improve health related quality of life (HRQoL) and to reduce cough frequency in patients 79 
with refractory chronic cough. 80 
Methods In this multi-centre randomised controlled trial, patients with refractory chronic 81 
cough were randomised to four weekly 1:1 sessions of either: PSALTI consisting of 82 
education, laryngeal hygiene and hydration, cough suppression techniques, breathing 83 
exercises and psycho-educational counselling or control intervention consisting of healthy 84 
lifestyle advice. We assessed the change in health related quality of life at week 4 with the 85 
Leicester Cough Questionnaire (LCQ). Secondary efficacy outcomes included 24-hour 86 
objective cough frequency (Leicester Cough Monitor) and cough reflex sensitivity. The 87 
primary analysis used an analysis of covariance adjusted for baseline measurements with the 88 
intention-to-treat population. This study was registered at UK Clinical Research Network 89 
(UKCRN ID 10678) 90 
Findings Between December 2011, and April 2014, we randomly assigned 75 patients who 91 
underwent baseline assessment (34 PSALTI and 41 control). In the observed case analysis, 92 
HRQoL (LCQ) improved on average by 1.5 (95%CI: 0.21 to 2.85) points more in PSALTI 93 
group than with control (p=0.024). Cough frequency improved by 41% (95%CI: 36% to 95%) 94 
in PSALTI group relative to control (p=0.030). The improvements within the PSALTI group 95 
were sustained up to three months. There was no significant difference between groups in the 96 
concentration of capsaicin causing 5 or more coughs.  97 
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Interpretation Greater improvements in HRQoL and cough frequency were observed with 98 
PSALTI intervention.  Our findings support the use of PSALTI for patients with refractory 99 
chronic cough. 100 
 101 
 102 
  103 
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INTRODUCTION 104 
Chronic cough, defined as a cough lasting more than eight weeks, [1] is a prevalent disorder 105 
in both the community, [2] and secondary care sectors, accounting for up to 20% of 106 
respiratory out-patient clinic referrals. [1, 3] The most common causes of cough in a non-107 
smoking patient with a normal chest radiograph and spirometry are asthma, gastro-108 
oesophageal reflux disease, and rhinitis (upper airway cough syndrome). [1, 4, 5] For a 109 
significant number of patients, the cough may remain unexplained or refractory to treatment 110 
despite extensive investigation and therapeutic trials. [6] Cough is associated with significant 111 
physical and psychological morbidity as well as impaired quality of life. [7-9] There are few 112 
effective antitussive therapies for refractory chronic cough. [10, 11] Recent studies suggest a 113 
potential role for gabapentin, pregabalin, amitriptyline, morphine and P2X3 receptor 114 
inhibitors but they are all associated with significant side effects. [12-16]  115 
 116 
Non-pharmacological therapies for refractory chronic cough have shown promising results in 117 
a few studies and no significant adverse effects. [17] Non-pharmacological therapies are 118 
generally delivered by physiotherapists or speech and language therapists and key 119 
components include: education, cough suppression techniques including breathing exercises, 120 
vocal hygiene and hydration and psycho-educational counselling. [15, 17-23] Vertigan et al, 121 
[19] conducted the only  randomised controlled trial of a non-pharmacological intervention 122 
for refractory chronic cough and found  significantly greater improvements in symptoms of 123 
cough for speech pathology management compared to control (general healthy lifestyle 124 
advice). The benefits of speech pathology management on objectively measured cough 125 
frequency, cough reflex sensitivity and health related quality of life (HRQoL) have not been 126 
assessed in a controlled clinical trial, limiting the generalisability of the findings. The 127 
minimal clinically important difference of the cough symptom score used in this study has not 128 
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been defined. Furthermore, the longer term effect of therapy is not known. [17] A recent 129 
study by Patel et al [20] investigated cough-suppression physiotherapy for refractory chronic 130 
cough in 23 participants and found a significant improvement in cough related quality of life 131 
but this study also did not include a control intervention.  132 
 133 
This study therefore aimed to assess the effect of an intervention utilising both physiotherapy 134 
and speech and language therapy techniques (Physiotherapy, Speech and Language Therapy 135 
Intervention, PSALTI) on HRQoL, objective cough frequency, cough reflex sensitivity and 136 
cough severity using a randomised controlled design. 137 
 138 
METHODS 139 
A multi-centre, single blinded randomised controlled trial was conducted across three 140 
hospitals in the UK (King’s College Hospital NHS Foundation Trust, Lancashire Teaching 141 
Hospitals NHS Foundation Trust and Northumbria Healthcare NHS Foundation Trust). Two 142 
further sites, Royal Brompton & Harefield NHS Foundation Trust and Guy’s and St Thomas’ 143 
NHS Foundation Trust) were recruitment only sites and patients were referred to King’s 144 
College Hospital to receive the intervention. The study was undertaken between December 145 
2011 and April 2014. 146 
 147 
Participants and randomisation 148 
Eligible patients were identified as adults with chronic cough (defined as duration greater 149 
than 2 months), with normal chest x-ray, minimal sputum production (less than 10ml sputum 150 
a day) and who had negative investigations and/or failed treatment trials for asthma, 151 
gastroesophageal reflux and, rhinitis as per British Thoracic Society guidelines. [1] Patients 152 
were excluded if they: had an upper respiratory tract infection in past four weeks, were taking 153 
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angiotensin converting inhibitor (ACE-I) medication, were current smokers, or had a known 154 
respiratory disease (such as lung cancer, pneumonia, pulmonary fibrosis, sarcoidosis, pleural 155 
effusion, bronchiectasis). Patients were also excluded if they had vocal cord nodules, 156 
malignancy, or evidence of active aspiration.  157 
 158 
Once participants had given written consent and completed baseline assessments, they were 159 
registered into the randomisation service provided by the King’s Clinical Trials Unit, King’s 160 
College London. This prevented foreknowledge of treatment assignment for the study 161 
researchers. Group allocation was concealed from participants until they had completed the 162 
study and all post-intervention assessments. Patients were block randomised, stratified by age 163 
(above and below 50 years old) and gender.  164 
 165 
Control intervention 166 
Participants attended weekly sessions and received one to one standardised healthy lifestyle 167 
advice from a health care professional (nurse, physiotherapist or speech and language 168 
therapist) over four weeks. The control intervention was based on that used in the trial 169 
reported by Vertigan et al. [19] The initial session covered general advice on exercise and 170 
physical activity, second session dietary and nutritional advice, third session stress 171 
management and fourth session relaxation. The material covered in each session was based 172 
on healthy lifestyle advised by the United Kingdom Department of Health and National 173 
Health Service. [24-26] The sessions were standardised for all sites by using the same written 174 
prompts for therapists and educational information. Face to face training was provided for all 175 
site therapists who delivered the healthy lifestyle intervention.  The duration of all trial 176 
sessions was 45 minutes except the initial session which was one hour. 177 
 178 
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PSALTI intervention 179 
Participants attended weekly sessions, and received one to one treatment from a health care 180 
professional (physiotherapist or speech and language therapist) over four weeks. Session 181 
durations were the same as for the control group. The intervention was based on previous 182 
speech pathology management and cough-suppression physiotherapy studies for refractory 183 
chronic cough reported by Vertigan et al and Patel et al respectively (Table 1). [19, 20] The 184 
first session focused on educating participants about chronic cough, introduction to laryngeal 185 
hygiene and hydration techniques and cough suppression/distraction. The second and third 186 
sessions covered cough suppression techniques in more detail including breathing exercises 187 
(table 1). Nasal douching or steam inhalations were recommended to patients with nasal 188 
congestion. In the third session psycho-educational counselling techniques were covered with 189 
the aid of an information booklet developed jointly by the lead researcher and clinical 190 
psychologist at the primary research site. The fourth session consisted of reinforcing all 191 
aspects of PSALTI. All components of PSALTI were delivered, however the focus and 192 
emphasis on individual techniques varied for each participant, determined by the treating 193 
therapist. Airway clearance techniques were included in the PSALTI treatment if the 194 
participant’s sputum production was close to the upper limit of sputum exclusion criteria. The 195 
standardisation of treatment between different hospitals was increased by the use of written 196 
treatment plans and educational material.  All therapists delivering the treatment were trained 197 
in PSALTI prior to commencing the study by the main study researcher.  198 
 199 
 200 
 201 
 202 
Table 1: PSALTI components  203 
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 204 
PSALTI 
component 
Technique 
Education Educate patients on the cough reflex, chronic cough and cough reflex 
hypersensitivity. 
Explain the negative effects of repeated coughing 
Educate patients on voluntary control of cough 
Laryngeal 
hygiene and 
hydration 
Increase frequency and volume of water and non-caffeinated drinks 
Reduce caffeine and alcohol intake 
Promote nasal breathing 
Cough control Teach patients to identify their cough triggers 
Teach patients to use cough suppression or distraction techniques at 
the first sign or sensation of the need or urge to cough. These cough 
suppression/distraction techniques include: forced swallow, sipping 
water and sucking sweets. 
Teach patients breathing exercises: breathing pattern re-education 
promoting relaxed abdominal breathing pattern technique; pursed lip 
breathing to use to control cough. 
Psycho-
educational 
counselling 
Motivate patients, reiterate the techniques and the aims of therapy 
Behaviour modification: to try to reduce over-awareness of the need 
to cough 
Stress and anxiety management 
Modified from Chamberlain et al [18] 205 
 206 
Primary Efficacy Endpoint 207 
HRQoL was assessed with the Leicester Cough Questionnaire (LCQ) at week four, the 208 
primary endpoint. [8] The LCQ is a validated 19-item cough-specific health-related quality of 209 
life questionnaire. Overall scores range from three to twenty-one with a higher score 210 
indicating a better HRQoL. The minimal important difference for this outcome is 1.3. [27]   211 
Participants independently completed questionnaires at baseline, at four weeks (after 4th 212 
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treatment session) and at three month follow up. Questionnaires were then placed in sealed 213 
envelopes to avoid influencing the treating therapist. 214 
 215 
Secondary Efficacy Endpoints 216 
Secondary endpoints were assessed at baseline, 4 weeks and 3 months. Objective cough 217 
frequency was assessed with the Leicester Cough Monitor (LCM) a validated, objective, 218 
automated and ambulatory cough monitoring device. [28] The LCM consists of a MP3 219 
recording device (Phillips 662 MP3 recorder, UK), external microphone and automated cough 220 
detection software. The LCM has been used in previous clinical trials of gabapentin and 221 
erythromycin. [12, 29] Participants wore the device for 24 hours at baseline, at four weeks 222 
(after fourth treatment session) and three month follow up and were instructed to resume their 223 
normal daily activities during this time period. The number of coughs per hour (CFperhour) 224 
were recorded. 225 
 226 
Capsaicin cough challenge was assessed in a subset of the participants (Kings College 227 
Hospital Foundation Trust and Northumbria Healthcare NHS Foundation Trust) to measure 228 
participants’ cough reflex sensitivity at baseline and at four weeks (after fourth treatment 229 
session). Doubling concentrations of capsaicin solution ranging from 0 (saline), 0.49µm to 230 
1000 µm were administered as per European Respiratory Society guidelines. [30] A dose-231 
response capsaicin cough testing method was used. [30] The nebuliser output was set to 232 
0.01mL.breath-1. The test was discontinued when five or more coughs were induced (C5). In 233 
addition, the dose that induced two or more coughs (C2) was recorded.  234 
 235 
Cough severity in the past 2 weeks was assessed by a visual analogue scale (0-100mm) as per 236 
American College of Chest Physicians guidelines. [31] The vocal performance questionnaire 237 
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(VPQ), [32] a 12 item tool was used to assess patients’ perceived impact on their voice, since 238 
a high prevalence of voice disorders in patients with chronic cough has been reported [33]. A 239 
score >12 indicates dysphonia. [32] General health and mood was assessed by Short-Form 36 240 
(SF36) and Hospital Anxiety and Depression scale (HADs). [34, 35] HADs is 14-item 241 
questionnaire, a score for either subscale ≥eight indicates mild symptoms, ≥11 moderate and 242 
≥15 severe. SF-36 generates two summary scores, physical component summary score (PCS) 243 
and mental component summary score (MCS); both range from zero to hundred and a higher 244 
score indicates better self-reported health. [36] 245 
 246 
Ethics and trial registration 247 
All protocols were approved by the London-Chelsea National Research Ethics Service 248 
(NRES) Committee (11-LO-0504). All participants provided written informed consent, and 249 
the study was registered with the UK Clinical Research Network (UKCRN ID 10678) and 250 
ISRCTN (ISRCTN 73039760). 251 
 252 
Role of funding source  253 
The funding bodies had no role in study design, collection, analysis and interpretation of data, 254 
in the writing of the report or in the decision to submit for publication. 255 
 256 
STATISTICAL ANALYSIS AND SAMPLE SIZE 257 
Power calculations for the primary outcome (LCQ score) were performed based on estimates 258 
from a previous study, [37] reporting a mean LCQ score in patients with chronic cough of 259 
14.03 (SD: 3.87). [37] Group sample sizes of 33 in each group achieve 80% power with a 260 
significance level of 5% to detect a LCQ change of 2.7 (seen in our pilot study). Allowing for 261 
a 25% drop out we aimed to recruit 88 patients in total.  262 
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 263 
For each of the variables analysed, univariate descriptive statistics were summarised by 264 
randomised group to provide an overview of the data. Summary measures for the baseline 265 
characteristics of each group were presented as mean and standard deviation for continuous 266 
‘approximate’ normally distributed variables, medians and interquartile ranges for non-267 
normally distributed variables, and frequencies and percentages for categorical variables. 268 
Univariate analyses were performed to compare study group using appropriate statistical tests 269 
according to the type and the distribution of the data: independent t-test or Mann-Whitney for 270 
continuous variable. Cough frequency and capsaicin data were log transformed prior to 271 
analysis.  272 
 273 
Primary efficacy analysis, change in LCQ at week 4, was based on analysis of covariance 274 
(ANCOVA) adjusted for the baseline LCQ measurements. The ANCOVA analysis was 275 
repeated to adjust for centre and speciality of treating therapist. The analysis used data from 276 
the intention-to-treat basis (ITT) population, which included all randomised participants who 277 
had received at least one treatment session. In this analysis only observed data were included 278 
and no imputation was used for missing data.  We also performed an analysis on a per-279 
protocol population (PP) which included patients who completed end of treatment (week 4) 280 
cough assessments and who did not deviate from the protocol (established before unmasking). 281 
Sensitivity analyses were performed for missing data according to different predefined 282 
populations using ANCOVA, with multiple imputations (Online appendix - Table 1). [38] 283 
Similar sensitivity analyses were also performed for objective log-transformed cough 284 
frequency endpoints (Online appendix - Table 2). 285 
 286 
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The secondary efficacy analysis used data from the intention-to-treat population. In these 287 
analyses ANCOVA was used adjusting for baseline variables and only observed data were 288 
included without imputation for missing data. A p-value of less than 0.05 was considered 289 
statistically significant.  All analyses were made using STATA version 12 software 290 
(StataCorp LP, College Station, TX).   291 
 292 
RESULTS  293 
Participants 294 
Seventy-five participants were randomised and had baseline assessments. One additional 295 
patient was randomised to the PSALTI group but did not attend baseline assessments. Four 296 
participants did not receive any treatment (PSALTI group (n=3): myocardial infarction prior 297 
to treatment, unable to travel to hospital and insufficient time for the study;  control group 298 
(n=1): undisclosed illness prior to start of treatment). The intention to treat population for 299 
LCQ primary analysis consisted of 71 participants (Figure 1 and Online Appendix - Table 1). 300 
A total of four participants in the control group and eight participants in the PSALTI group 301 
did not receive or complete all treatments for reasons stated in Figure 1. Forty-nine 302 
participants completed three month follow up. The consort study flow is described in Figure 303 
1. The baseline characteristics of the randomised participants are described in Table 2. The 304 
groups were  well-matched with the exception of SF36 Physical Component Summary Scores 305 
(higher in the control group).     306 
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Table 2. Baseline demographic and clinical characteristics of randomised study participants. 307 
 308 
Characteristic 
 
Control (n=41) PSALTI (n=34) p 
value 
Age (years)  56 (48 to 67)  61 (53 to 67) 0.239 
Female, n (%)  26 (63)  25 (71) 0.459 
Cough duration (months)  48 (24 to 126)  60 (30 to 126) 0.279 
FEV1 (L, observed), mean(SD)  2.7 (0.9)  2.6 (0.7) 0.517 
FEV1/FVC (%), mean(SD)  76 (8.2)  76  (5.0) 0.686 
LCQ, mean(SD)  11.9 (3.5)  10.4 (3.6) 0.073 
Cough Severity VAS  65 (40 to 83)  63 (49 to 75) 0.652 
SF-36 PCS,   47.1 (41.7 to 53.6)  41.1 (35.6 to 49.1) 0.033* 
SF-36 MCS  47.7 (38.3 to 54.9)  49.9 (40.5 to 57.0) 0.763 
HADs –Anxiety  7 (3 to 10)  7 (4 to 10) 0.785 
HADs – Depression  4 (1 to 8)  5 (2 to 6) 0.620 
VPQ  17 (11 to 22)  21 (13 to 27) 0.158 
CFperhour #  17.0 (0.4)  17.0 (0.4) 0.983 
C2 (µm) #  4.01(0.69)  4.74 0.62) 0.677 
C5 (µm) #  9.33 (0.56)  8.25 (0.51) 0.708 
Data presented as median (IQR) unless otherwise stated.  309 
 310 
*p<0.05, # Geometric mean (log SD) 311 
 312 
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; LCQ, Leicester cough questionnaire; 313 
VAS, visual analogue scale; SF-36, short-form 36 questionnaire; PCS, Physical component score; MCS, Mental 314 
component score; HADs, hospital anxiety and depression scale; VPQ, vocal performance questionnaire; 315 
CFperhour, cough frequency per hour over a 24 hour period; C2, capsaicin cough challenge –  concentration that 316 
resulted in two or more coughs;  C5, capsaicin cough challenge –  concentration that resulted in five or more 317 
coughs. 318 
 319 
HRQoL - Primary Efficacy Endpoint 320 
 321 
There was an improvement in the mean total LCQ score at four weeks with PSALTI; baseline 322 
10.4 vs. four-weeks 14.4, mean difference 3.4, p<0.001. This improvement was larger than 323 
that in the control group; baseline mean 11.9 vs. 13.4 at four-weeks, mean difference 1.66, 324 
p<0.001 (Online Appendix – Table 3). Total LCQ score at four weeks improved by a mean 325 
1.53 (95% CI 0.21 to 2.85) units more in the PSALTI group than in control (p=0.024), table 3.  326 
When adjusted for centre and speciality of therapist, the LCQ score at four weeks improved 327 
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by a mean of 1.53 (95% CI 0.20 to 2.86), p=0.024. The improvement in LCQ with PSALTI  328 
was consistent in the per-protocol and sensitivity analyses (Online Appendix - Table 1). The 329 
LCQ improvement was sustained from week 4 to  3 months for both groups but there was no 330 
significant difference between groups at 3 months (table 3). The LCQ scores and within 331 
group differences are presented in online supplement Table 3 and Table 4 respectively.  332 
Primary outcome LCQ data (baseline or week 4) was missing in 6.7% of participants. There 333 
were no adverse or serious adverse events reported for both interventions. 334 
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Table 3. Primary and Secondary efficacy endpoint analysis: Change between PSALTI and control groups at baseline to four weeks and four weeks to three month 
follow up 
 
 Between group difference 
Baseline to four weeks 
Between group difference 
Four weeks to three month follow up 
Mean Difference (95% CI) p value Mean Difference (95% CI) p value 
LCQ Total     1.53 (0.21 to 2.85)      0.024         0.01 (-1.62 to 1.64) 0.994 
CFperhour (fold change)     0.59 (0.36  to 0.94)      0.030         1.01 (0.55 to 1.86)         0.966 
VAS severity    -9.72 (-20.80 to 1.36)      0.084         1.6 (-15.48 to 18.74) 0.848 
SF36 PCS     0.56 (-2.52 to 3.64)      0.717         0.48 (-3.27 to 3.37) 0.977 
SF36 MCS     0.81 (-3.10 to 4.72)      0.680         0.72 (-3.06 to 4.51) 0.703 
VPQ     3.90 (-0.33 to 8.12)      0.070        -0.20 (-3.43 to 3.03) 0.901 
HADS – Anxiety    -0.42 (-1.96 to 1.13)      0.590         0.88 (-0.57 to 2.34) 0.225 
HADS – Depression    -0.44 (-1.69 to 0.81)      0.486        -0.18 (-1.36 to 0.99) 0.753 
C2 (fold change)     1.11 (0.76 to 1.61)      0.575 NA NA 
C5 (fold change)     1.11 (0.80 to 1.54)      0.512 NA NA 
 
Between group differences were calculated using ANCOVA adjusted for baseline values.  
Positive change in LCQ, SF36 PCS, SF36 MCS, and C5 indicates improvement in symptoms. Negative change in VAS, VPQ, HADS indicates improvement in 
symptom.  
LCQ, Leicester cough questionnaire; CFperhour, cough frequency per hour over a 24 hour period; VAS, visual analogue scale; SF-36, short-form 36 questionnaire; 
PCS, Physical component score; MCS, Mental component score; VPQ, vocal performance questionnaire HADS, hospital anxiety and depression scale; C2, 
concentration of capsaicin that caused ≥2 coughs, C5,concentration of capsaicin that caused ≥5 coughs, NA – not assessed at this time point. 
                   *p<0.05 
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Objective Cough Frequency 337 
There was a greater reduction in cough frequency after four weeks of treatment in the 338 
PSALTI group; geometric mean (SD) 17.0 (2.4) to 9.0 (3.3) coughs per hour (p=0.002) versus 339 
17.0 (2.3) to 16.0 (2.2) coughs per hour after control (p=0.205), table 4. The control-adjusted 340 
improvement in cough frequency per hour in PSALTI was 41% (95% CI [36-95%], p=0.030, 341 
ANCOVA) at 4 weeks in the primary ITT analysis, (table 3). This improvement was also 342 
sustained at three months (Figure 2).  The reduction in cough frequency with PSALTI was 343 
consistent in per-protocol and sensitivity analyses (Online Appendix - Table 2).  344 
 345 
Other questionnaire data 346 
There were no significant between group differences for change (week four minus baseline) 347 
in VPQ, depression, anxiety or SF36 (Table 3).  There was a greater reduction in VAS cough 348 
severity in the PSALTI group compared to control (p=0.084, Table 3). There was a reduction 349 
in cough severity VAS within groups between week 4 to baseline; control p=0.007, PSALTI 350 
p<0.001 (Table 4).  351 
 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
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Table 4: Primary and Second Efficacy Endpoints : within group change  
 Change from baseline to  four weeks Change from four weeks to three month follow up 
PSALTI 
Mean Difference      
(95% CI) 
P Control 
Mean Difference 
(95% CI) 
P PSALTI 
Mean Difference 
(95% CI) 
P Control 
Mean Difference (95% 
CI) 
P 
LCQ Total mean 3.40                                
(2.26 to 4.55) 
 0.001* 1.66                      
(0.78 to 2.54) 
<0.001* -0.17                          
(-1.49 to 1.15) 
0.794 0.27                              
(-0.82 to 1.35) 
0.616 
CFperhour (fold change) 0.55                             
(0.33 to 0.75) 
0.002 0.82                        
(0.60 to 1.22) 
0.2053 1.26                         
(0.84 to 1.90) 
0.236 0.91                               
(0.59 to 1.39) 
0.655 
VAS severity -21.18                              
(-29.83 to -12.53) 
<
0.001* 
-11.84                        
(-20.11 to -3.57) 
0.007* 9.74                           
(-3.60 to 23.08) 
0.143 0.79                              
(-10.73 to 12.31) 
0.888 
C2 (fold change) 1.28                            
(0.96 to 1.71) 
0.089 1.06                       
(0.81 to 1.36) 
0.666 NA NA NA NA 
C5 (fold change) 1.24                                
(1.02 to 1.50) 
0.035* 1.08                              
(0.87 to 1.36) 
0.469 NA NA NA NA 
SF36 PCS 1.62                                   
(-0.96 to 4.21) 
0.208 0.50                               
(-1.30 to 2.31) 
0.574 0.54                           
(-1.82 to 2.89) 
0.639 0.76                              
(-1.66 to 3.18) 
0.522 
SF36 MCS 0.53                                   
(-2.69 to 3.75) 
0.736 -0.26                            
(-2.92 to 2.40) 
0.843 1.09                             
(-1.91 to 4.09) 
0.456 0.49                               
(-2.35 to 3.32) 
0.727 
VPQ 4.04                                   
(0.12 to 7.97) 
 0.044* 0.73                              
(-1.94 to 3.39) 
0.582 -1.63                           
(-4.17 to 0.91) 
0.193 -0.57                             
(-3.29 to 2.15) 
0.666 
HADS – Anxiety -1.27                                
(-2.51 to -0.032) 
0.045* -0.90                            
(-1.96 to 0.17) 
0.095 -0.11                               
(-1.16 to 0.94) 
0.826 0.95                                 
(-0.22 to 2.11) 
0.104 
HADS – Depression -0.68                                 
(-1.57 to 0.21) 
0.126 -0.21                             
(-1.11 to 0.69) 
0.641 0.06                           
(-1.42 to 1.53) 
0.937 0.05                              
(-0.66 to 0.76) 
0.878 
 
Positive change in LCQ, SF36 PCS, SF36 MCS indicates improvement in symptoms. Negative change in VAS, VPQ and HADS indicates improvement in symptoms. LCQ, 
Leicester cough questionnaire; CFperhour, cough frequency per hour over a 24 hour period; C2, capsaicin cough challenge concentration that resulted in two or more coughs - 
C5, capsaicin cough challenge –  concentration that resulted in five or more coughs; VAS, visual analogue scale; SF-36, short-form 36 questionnaire; PCS, Physical 
component score; SF-36 MCS, Mental component score; VPQ, vocal performance questionnaire HADS, hospital anxiety and depression scale. NA – not assesses at this 
timepoint 
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Cough reflex sensitivity 361 
Sixty participants (80% of ITT group) underwent capsaicin challenge. No significant 362 
differences between groups were observed for C2 (p=0.575) or C5 (p=0.512) (Table 3).  There 363 
was a within group reduction in C5 with PSALTI (p=0.035) but not with control (p=0.469), 364 
table 4. 365 
  366 
DISCUSSION 367 
 368 
This study evaluated the efficacy of a physiotherapy and speech and language therapy 369 
intervention for patients with refractory chronic cough in a randomised controlled trial.   370 
There was a clinically and statistically significant improvement in health-related quality of 371 
life with PSALTI compared to control intervention.   This was supported by a significant 372 
reduction in cough frequency measured objectively.  The improvement in health-related 373 
quality of life was sustained at a three-month follow-up visit.   There was no significant 374 
change in cough reflex sensitivity between groups. 375 
 376 
Our findings represent an advance from those reported in an earlier study by Vertigan et al. 377 
[19]   Our study is the first multi-centre trial reported in chronic cough and has the potential 378 
to provide the evidence base for access to therapy. Vertigan et al reported a statistically 379 
significant reduction in cough symptoms scores but did not include HRQoL or objective 380 
assessment with cough frequency monitors. [19]   In contrast we assessed HRQoL, objective 381 
cough frequency, cough severity VAS and cough reflex sensitivity.  We were also able to 382 
demonstrate both a clinically and statistically significant improvement in our primary 383 
endpoint because the minimally important difference (MID) of the LCQ has been defined. 384 
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[27] We have shown that the benefits of PSALTI are sustained after discontinuation of 385 
therapy, in contrast to Vertigan et al who did not report follow up data for their participants. 386 
[19] One of the strengths of our study was the involvement of multiple centres, the use of 387 
standardised treatment protocols and the inclusion of both physiotherapists and speech and 388 
language therapists delivering the treatment.  389 
 390 
HRQoL, as assessed with the Leicester Cough Questionnaire (LCQ) was selected as the 391 
primary outcome measure because it is perhaps the most important outcome measure from the 392 
patient’s perspective. [7, 8, 39] The HRQoL of our patients was severely impaired, affecting 393 
physical, psychological and social domains, comparable to that reported in previous studies of 394 
refractory chronic cough. [29, 40] The improvement of HRQoL with PSALTI was large, 395 
LCQ 3.4 units.   This improvement was greater than the MID of the LCQ, 1.3 units, [27] and 396 
that reported for Gabapentin therapy in patients with refractory chronic cough (LCQ 397 
improvement 2.5 units). [12] The improvement with PSALTI was smaller when adjusted for 398 
the change in the control group (LCQ score control group 1.66 units). HRQoL also improved 399 
with control intervention, but to a lesser extent than PSALTI.  The aim of the control 400 
intervention was to provide patients with an equivalent quantity of clinical attention to the 401 
PSALTI intervention.   This is additional to what most patients with  refractory chronic cough 402 
would receive as usual care since physiotherapy and speech and language therapy services are 403 
not widely available for refractory chronic cough.  It is possible that the control intervention 404 
had an anti-tussive effect and that the difference between PSALTI and control group may 405 
have been larger if compared to usual care (no active treatment). The control intervention was 406 
intended to be non-specific but it is possible that some of its components such as 407 
stress/anxiety and lifestyle management may have had a positive benefit, particularly on the 408 
central sensitisation pathways that regulate cough. 409 
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 410 
The improvement in cough frequency assessed objectively with 24-hour cough monitoring 411 
supports the improvement in HRQoL with PSALTI occurred because of an actual reduction 412 
in coughing.   Cough frequency outcome measures are increasingly being used as end-points 413 
in clinical trials to validate the efficacy of anti-tussive therapy. [41, 42] The Leicester Cough 414 
Monitor (LCM) has been reported to be a valid method of counting coughs objectively. [28, 415 
43] An advantage of cough monitors over subjective measures is that they are not susceptible 416 
to the patient’s or clinician’s perception of cough severity.   PSALTI intervention was 417 
associated with an additional 41% reduction in cough frequency, which can be considered a 418 
large change and is comparable to that observed with pharmacotherapy such as the P2X3 419 
inhibitor AF-219. [13] The minimal clinically important difference for cough monitor 420 
frequency in chronic cough has not been studied.  The reduction of cough frequency was 421 
comparable to the minimal important difference reported for acute cough. [42] We also 422 
assessed cough severity subjectively with VAS.   There was a reduction in cough severity 423 
with PSALTI compared to control intervention, and the difference approached statistical 424 
significance.  The reason for the discrepancy in effect size between HRQoL and VAS 425 
findings is not clear.   A larger study would be needed to confirm whether PSALTI impacts 426 
cough assessed with VAS. Despite their widespread use, VAS have been poorly validated in 427 
comparison to HRQoL questionnaires and cough monitoring tools, as acknowledged by the 428 
American College of Chest Physicians’ Cough Guidelines. [31] There were no between group 429 
differences in reported voice related problems. We chose the VPQ, a patient reported 430 
questionnaire, to assess voice since it has been reported to have excellent internal consistency, 431 
repeatability and responsiveness. [44] There are alternative questionnaires available to assess 432 
voice such as the voice handicap index and voice symptom scale [45, 46].  A comparison of 433 
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these scales by Webb et al concluded all were valid and reliable questionnaires for assessing 434 
patient’s perceived voice dysfunction [44]. 435 
There were no adverse events associated with PSALTI, specifically no episodes of pulmonary 436 
infections.  Patients with significant sputum production were excluded because of the 437 
potential risk of pulmonary infections associated with cough suppression.  Longer-term data 438 
with PSALTI is required to fully assess its safety.   The mechanism by which PSALTI 439 
reduces cough is not clear, nor which component of PSALTI is most effective.   PSALTI was 440 
not associated with a reduction in cough reflex sensitivity assessed with capsaicin when 441 
compared to the change in control group. There was however a significant within group reduction 442 
in C5 in the PSALTI group which is consistent with studies by Ryan et al and Vertigan et al, who 443 
reported a reduction in cough reflex sensitivity with speech pathology management. [15, 21] 444 
The Ryan et al and Vertigan et al studies however did not have a control group (no speech 445 
pathology management) for comparison. It is possible that we did not find a between group 446 
difference in cough reflex sensivity due to the small sample size of participants that 447 
underwent capsaicin cough challenge testing; further studies are needed to investigate this. 448 
[15, 21] 449 
  450 
We investigated PSALTI in patients with refractory chronic cough.  Our patients had a 451 
troublesome chronic cough despite numerous investigations and trials of therapy. A refractory 452 
chronic cough may also be referred to as idiopathic, difficult to treat, unexplained, sensory 453 
neuropathic and vagal neuropathy cough although some differences exist between groups. 454 
[47] PSALTI type treatments have only been studied in patients with refractory chronic cough 455 
once they have undergone extensive investigations and/or trials of therapy. The role of 456 
PSALTI type treatments earlier in the management of such patients has not been explored and 457 
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needs to be studied. The efficacy of PSALTI is also unknown in other difficult to treat 458 
coughs, such as that associated with lung cancer, idiopathic pulmonary fibrosis and 459 
sarcoidosis and this should be investigated. Further studies are needed to explore the optimum 460 
frequency and duration of PSALTI and other non-pharmacological treatments. 461 
 462 
There were some limitations to our study.  The study was single-blinded.  It was not possible 463 
to blind the treating therapist to the intervention the patient received.   The possibility that 464 
unconscious bias could have been conveyed to participants during the course of intervention 465 
cannot therefore be discounted. Double blinding is not possible in studies of behavioural 466 
intervention. The potential bias was minimised by asking patients to complete their primary 467 
outcome measures independently from the treating therapist and participants remained 468 
blinded until after completion of the final post-intervention outcome measures. Capsaicin 469 
cough reflex tests in some patients were performed by the treating therapist but it is unlikely 470 
this influenced the outcome since our findings  suggest no change with intervention when 471 
adjusted for control. Some components of PSALTI were tailored to the individual, according 472 
to clinical need. This may be considered both a limitation and a strength since it reduces the 473 
uniformity of intervention delivered but reflects real life clinical practice addressing the needs 474 
of an individual.  Our study did not meet the intended sample size. This may have affected the 475 
power of our analyses and undermined the robustness of the results. Despite this, there was a 476 
clinically and statistically significant improvement in the primary outcome measure with 477 
PSALTI. Thirty-six (22%) of subjects screened were uncontactable or declined to participate. 478 
The clinical characteristics of participants recruited were however consistent with previously 479 
reported studies of refractory chronic cough [29]. A significant number of patients were lost 480 
to follow up for the 3 month visit where secondary endpoints were assessed. This was largely 481 
from the control group. There was no significant difference in LCQ between groups at 3 482 
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months; this could be a consequence of a smaller sample size or a reduction in the long term 483 
benefit of PSALTI following cessation of therapy. The long term benefits of PSALTI needs 484 
to be confirmed in larger studies. It is possible that some of the benefit of PSALTI may have 485 
been a consequence of intense supervision. The control intervention was however identical in 486 
frequency and duration of visits.  487 
 488 
In conclusion, PSALTI is an effective therapy for patients with refractory chronic cough.   It 489 
is associated with a significant improvement in health-related quality of life, and cough 490 
frequency compared to control.   The optimal components of PSALTI and number of sessions 491 
of therapy need to be determined in future studies.   The effectiveness of PSALTI used earlier 492 
in the treatment of chronic cough and other patient groups with difficult-to-treat cough, 493 
should be evaluated.  There is also a need for improved access to physiotherapy and speech 494 
and language therapy services for patients with refractory chronic cough. 495 
 496 
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FIGURE LEGENDS 536 
 537 
Figure 1. Trial CONSORT flow diagram 538 
 539 
Figure 2. Change in objective cough frequency in PSALTI and control groups  540 
 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
 Page 29 of 35 
 
REFERENCES 558 
1. Morice, A.H., McGarvey, L., Pavord, I. On behalf of the British Thoracic Society. 559 
Recommendations for the management of cough in adults. Thorax 2006; 61: Suppl 1: 560 
i1–24. 561 
 562 
2. Ford, A.C., Forman, D., Moayyedi, P., Morice, A.H. Cough in the community: a cross 563 
sectional survey and the relationship to gastrointestinal symptoms. Thorax 2006; 564 
61:11: 975–9. 565 
 566 
3. Morice, A. Chronic cough: epidemiology. Chron Respir Dis 2008; 5:1: 43–7. 567 
 568 
4. Morice, A.H., Fontana, G.A., Sovijarvi, A.R., et al., The diagnosis and management 569 
of chronic cough. Eur Respir J 2004; 24:3: 481–92. 570 
 571 
5. Irwin, R., Baumann, M.H., Bolser, D.C., et al., Diagnosis and management of cough 572 
executive summary: ACCP evidence-based clinical practice guidelines. Chest 2006; 573 
129: 1 Suppl: 1S–23S. 574 
 575 
6. Haque, R.A., Usmani, O.S., Barnes, P.J. Chronic idiopathic cough: a discrete clinical 576 
entity? Chest 2005; 127:5: 1710–3. 577 
 578 
7. Brignall, K., Jayaraman, B., Birring, S.S. Quality of life and psychosocial aspects of 579 
cough. Lung 2008. 186: Suppl 1: S55–8. 580 
 581 
 Page 30 of 35 
 
8. Birring, S.S., Prudon, B., Carr, A.J., Singh, S.J., Morgan, M.D., Pavord, I.D. 582 
Development of a symptom specific health status measure for patients with chronic 583 
cough: Leicester Cough Questionnaire (LCQ). Thorax 2003. 58:4: 339–43. 584 
 585 
9. French, C.L., Irwin, R.S., Curley, F.J., Krikorian, C.J. Impact of chronic cough on 586 
quality of life. Arch Intern Med 1998. 158:15:1657–61. 587 
 588 
10. Chung, K.F. Clinical cough VI: the need for new therapies for cough: disease-specific 589 
and symptom-related antitussives. Handb Exp Pharmacol 2009. 187: 343–68. 590 
 591 
11. Belvisi, M.G., Geppetti, P. Cough • 7: Current and future drugs for the treatment of 592 
chronic cough. Thorax 2004. 59:5: 438–440. 593 
 594 
12. Ryan, N.M., Birring, S.S., Gibson, P.G. Gabapentin for refractory chronic cough: a 595 
randomised, double-blind, placebo-controlled trial. Lancet 2012. 380:9853:1583–9. 596 
 597 
13. Abdulqawi, R., Dockry, R., Holt, K. et al. P2X3 receptor antagonist (AF-219) in 598 
refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 599 
study. Lancet, 2015. 385:9974: 1198–205 600 
 601 
14. Morice, A.H., Monon, M.S., Mulrennan, S.A., et al., Opiate therapy in chronic cough. 602 
Am J Respir Crit Care Med 2007. 175:4:312–5. 603 
 604 
 Page 31 of 35 
 
15. Vertigan, A.E., Kapela, S.L., Ryan, N.M., Birring, S.S., McElduff, P., Gibson, P.G. 605 
Pregablin and Speech Pathology Combination Therapy for Refractory Chronic Cough: 606 
A Randomized Controlled Trial. Chest 2016. 149:3:639-648. 607 
 608 
16. Jeyakumar, A., Brickman, T. M., Haben, M. Effectiveness of amitriptyline versus 609 
cough suppressants in the treatment of chronic cough resulting from postviral vagal 610 
neuropathy. Laryngoscope 2006. 116:12:2108–12. 611 
 612 
17. Chamberlain, S., Birring, S.S., Garrod, R. Nonpharmacological interventions for 613 
refractory chronic cough patients: systematic review. Lung 2014. 192:1: 75–85. 614 
 615 
18. Chamberlain, S., Garrod, R., Birring, S.S. Cough suppression therapy: does it work? 616 
Pulm Pharmacol Ther 2013. 26:5:524–7. 617 
 618 
19. Vertigan, A.E., Theodoros, D.G., Gibson, P.G., Winkworth, A.L. Efficacy of speech 619 
pathology management for chronic cough: a randomised placebo controlled trial of 620 
treatment efficacy. Thorax 2006. 61:12:1065–9. 621 
 622 
20. Patel, A.S., Watkin, G., Willig, B., et al. Improvement in health status following 623 
cough-suppression physiotherapy for patients with chronic cough. Chron Respir Dis 624 
2011. 8:4:253–8. 625 
 626 
21. Ryan, N.M., Vertigan, A.E., Bone, S., Gibson, P.G. Cough reflex sensitivity improves with 627 
speech language pathology management of refractory chronic cough. Cough 2010. 6:5. 628 
 629 
 Page 32 of 35 
 
22. Ryan, N.M., Vertigan, A.E., Gibson, P.G. Chronic cough and laryngeal dysfunction 630 
improve with specific treatment of cough and paradoxical vocal fold movement. 631 
Cough 2009. 5:4. 632 
 633 
23.     Vertigan, A., Theodoros, D., Winkworth, A., Gibson, P. Chronic cough a tutorial for 634 
speech-pathologists. Journal of medical speech-language pathology. Journal of 635 
Medical Speech-Language Pathology 2007. 15:3: 189–206.       636 
24. Department of Health (2011) Start Active, Stay Active. UK, Department of Health 637 
 638 
25.  NHS (2013) Eight tips for healthy eating. Available at 639 
http://www.nhs.uk/Livewell/Goodfood/Pages/eight-tips-healthy-eating.aspx [Accessed 640 
05/10/2015] 641 
 642 
26.  NHS (2013) Relaxation tips to relieve stress. Available at 643 
http://www.nhs.uk/Conditions/stress-anxiety-depression/Pages/ways-relieve-stress.aspx 644 
[Accessed 05/10/2015] 645 
                                                                                                    646 
27. Raj, A.A., Pavord, D.I., Birring, S.S. Clinical cough IV:what is the minimal important 647 
difference for the Leicester Cough Questionnaire? Handb Exp Pharmacol 2009. 648 
187:311–20.                                                                                      649 
28. Birring, S.S., Fleming, T., Matos, S., Rai, A.A., Evans, D.H., Pavord, I.D. The 650 
Leicester Cough Monitor: preliminary validation of an automated cough detection 651 
system in chronic cough. Eur Respir J 2008. 31:5:1013–8. 652 
 Page 33 of 35 
 
29. Yousaf, N., Monteiro, W., Parker, D., Matos, S., Birring, S., Pavord, I.D. Long-term 653 
low-dose erythromycin in patients with unexplained chronic cough: a double-blind 654 
placebo controlled trial. Thorax 2010. 65:12:1107–10. 655 
 656 
30. Morice, A.H., Fontana, G.A., Belvisi, M.G. et al. ERS guidelines on the assessment of 657 
cough. Eur Respir J 2007. 29:6:1256–76. 658 
 659 
31.      Boulet, L., Coeytaux, R.R., McCrory, D.C., et al. Tools for Assessing Outcomes in 660 
Studies of Chronic Cough: CHEST Guideline and Expert Panel Report. Chest 2015. 661 
147:3:804–14.  662 
 663 
32. Carding, P.N., Horsley, I.A. An evaluation study of voice therapy in non-organic 664 
dysphonia. Eur J Disord Commun 1992. 27:2:137–58. 665 
 666 
33.      Vertigan, A. E., Theodoros, D. G., Winkworth, A. L. and Gibson, P. G. Perceptual voice 667 
characteristics in chronic cough and paradoxical vocal fold movement.  Folia Phoniatr 668 
Logop 2007. 59:5:256-67. 669 
 670 
34. Brazier, J.E., Harper, R., Jones, N.M., et al. Validating the SF-36 health survey 671 
questionnaire: new outcome measure for primary care. BMJ 1992. 305:6846:160–4. 672 
 673 
35. Zigmond, A.S., Snaith, R.P. The hospital anxiety and depression scale. Acta Psychiatr 674 
Scand 1983. 67:6:361–70. 675 
 676 
 Page 34 of 35 
 
36. Lacson, E., Xu, J., Lin, S.F., Dean, S.G., Lazarus, J.M., Hakim, R.M. A comparison of 677 
SF-36 and SF-12 composite scores and subsequent hospitalization and mortality risks 678 
in long-term dialysis patients. Clin J Am Soc Nephrol 2010. 5:2:252–60. 679 
 680 
37. Birring, S.S., Pavord, I.D. Assessment of gender differences in health status with the 681 
Leicester Cough Questionnaire (LCQ). Thorax 2009. 64:11:1008–9. 682 
 683 
38. Little, R.J., D’Agostino, R., Cohen, M.L., et al., The prevention and treatment of 684 
missing data in clinical trials. N Engl J Med 2012. 367:14:1355–60. 685 
 686 
39. Spinou, A., Birring, S. S. An update on measurement and monitoring of cough: what 687 
are the important study endpoints? J Thorac Dis 2014. 6:Suppl 7: S728–34. 688 
40.  Birring, S.S., Murphy, A.C., Scullion, J.E., Brightling, C.E., Browning, M., Pavord, 689 
I.D. Idiopathic chronic cough and organ-specific autoimmune diseases: a case-control 690 
study. Respir Med 2004. 98:3:242–6. 691 
41.  Lee, K.K., Savani, A., Matos, S., Evans, D.H., Pavord, I.D., Birring, S.S. Four-hour 692 
cough frequency monitoring in chronic cough. Chest 2012.142:5:1237–43. 693 
42. Lee, K.K., Matos, S., Evans, D.H., White, P., Pavord, I.D., Birring, S.S. A 694 
Longitudinal Assessment of Acute Cough. American Journal of Respiratory and 695 
Critical Care Medicine 2013. 187:9:991–997. 696 
 697 
43.  Yousaf, N., Monteiro, W., Matos, S., Birring, S.S., Pavord, I.D. Cough frequency in 698 
health and disease. Eur Respir J 2013. 41:1:241–3. 699 
 700 
 Page 35 of 35 
 
44.      Webb, A. L., Carding, P. N., Deary, I. J., MacKenzie, K., Steen, I. N. and Wilson, J. A. 701 
Optimising outcome assessment of voice interventions, I: Reliability and validity of 702 
three self-reported scales. J Laryngol Oto 2007. 121:8: 763-7. 703 
 704 
45. Jacobson, B.H., Johnson, A., Grywalski, C., Silbergleit, A., Jacobson, G. Benninger, 705 
M.A., Newman, G.W. The Voice Handicap Index (VHI): Development and 706 
Validation. American Journal of Speech-Language Pathology 1997. 6:66-70.  707 
 708 
46. Dreary, I.J., Wilson, J.A., Carding, P.N., MacKenzie, K. VoiSS: a patient-derived 709 
Voice Symptom Scale. J PsychoSom Res 2003. 54:5:483-489. 710 
 711 
47.   Birring, S.S. Controversies in the evaluation and management of chronic cough. Am J 712 
Respir Crit Care Med 2011. 183:6:708-15. 713 
 714 
 715 
